A Phase 3, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A 20-valent Pneumococcal Conjugate Vaccine In Pneumococcal Vaccine-naive Adults 18 Years Of Age And Older
Phase of Trial: Phase III
Latest Information Update: 31 Dec 2018
At a glance
- Drugs PF 06482077 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate; Pneumococcal vaccine
- Indications Pneumococcal infections; Pneumonia
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Pfizer
- 17 Dec 2018 Status changed from not yet recruiting to recruiting.
- 29 Nov 2018 Status changed from planning to not yet recruiting.
- 26 Sep 2018 New trial record